| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11027072 | ADAMIS PHARMS CORP | Emergency devices |
May, 2039
(15 years from now) | |
| US11571518 | ADAMIS PHARMS CORP | Emergency devices |
Jun, 2041
(17 years from now) | |
Zimhi is owned by Adamis Pharms Corp.
Zimhi contains Naloxone Hydrochloride.
Zimhi has a total of 2 drug patents out of which 0 drug patents have expired.
Zimhi was authorised for market use on 15 October, 2021.
Zimhi is available in solution;intramuscular, subcutaneous dosage forms.
Zimhi can be used as a method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a window configured to allow the user to view the opioid antagonist in the syringe.
The generics of Zimhi are possible to be released after 14 June, 2041.
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a window configured to allow the user to view the opioid antagonist in the syring...
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZIMHI family patents
